Modulation of macrophage-lymphocyte interactions by the antiarthritic gold compound, auranofin

D. E. Griswold, J. C. Lee, George Poste, N. Hanna

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Auranofin (AF), a new oral gold agent effective for treating rheumatoid arthritis (RA), was evaluated for its ability to alter macrophage and lymphocyte functions of immune mediated chronic inflammation. AF (2 μM) inhibited antigen presentation by splenic macrophages to sensitized (DNFB) lymph node cells in vitro and also inhibited production of IL-2 and IL-1 by lymphocytes and macrophages, respectively. When AF suppressed Con-A induced mitogenesis in vitro, there were no inhibitory effects on Con-A induced suppressor T cell functions. AF administered orally to normal mice did not affect antigen presentation, DNFB contact sensitivity or Con-A induced mitogenesis. High concentrations of topical AF inhibited local immune responses to contact sensitizing agents and enhanced the induction of antigen specific suppressor T cells. Optimally, in vitro or in vivo AF inhibited macrophage and helper T cell functions with impairing the induction of suppressor T cells. After chronic treatment, similar effects could contribute to the efficacy of AF in humans with RA.

Original languageEnglish (US)
Pages (from-to)490-497
Number of pages8
JournalJournal of Rheumatology
Volume12
Issue number3
StatePublished - 1985
Externally publishedYes

Fingerprint

Gold Compounds
Auranofin
Macrophages
Lymphocytes
Dinitrofluorobenzene
Antigen Presentation
T-Lymphocytes
Rheumatoid Arthritis
Haptens
Contact Dermatitis
Helper-Inducer T-Lymphocytes
Interleukin-1
Gold
Interleukin-2
Lymph Nodes
Inflammation
Antigens

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Modulation of macrophage-lymphocyte interactions by the antiarthritic gold compound, auranofin. / Griswold, D. E.; Lee, J. C.; Poste, George; Hanna, N.

In: Journal of Rheumatology, Vol. 12, No. 3, 1985, p. 490-497.

Research output: Contribution to journalArticle

@article{79cd3ccf6d824f3eba71e1a19752a09e,
title = "Modulation of macrophage-lymphocyte interactions by the antiarthritic gold compound, auranofin",
abstract = "Auranofin (AF), a new oral gold agent effective for treating rheumatoid arthritis (RA), was evaluated for its ability to alter macrophage and lymphocyte functions of immune mediated chronic inflammation. AF (2 μM) inhibited antigen presentation by splenic macrophages to sensitized (DNFB) lymph node cells in vitro and also inhibited production of IL-2 and IL-1 by lymphocytes and macrophages, respectively. When AF suppressed Con-A induced mitogenesis in vitro, there were no inhibitory effects on Con-A induced suppressor T cell functions. AF administered orally to normal mice did not affect antigen presentation, DNFB contact sensitivity or Con-A induced mitogenesis. High concentrations of topical AF inhibited local immune responses to contact sensitizing agents and enhanced the induction of antigen specific suppressor T cells. Optimally, in vitro or in vivo AF inhibited macrophage and helper T cell functions with impairing the induction of suppressor T cells. After chronic treatment, similar effects could contribute to the efficacy of AF in humans with RA.",
author = "Griswold, {D. E.} and Lee, {J. C.} and George Poste and N. Hanna",
year = "1985",
language = "English (US)",
volume = "12",
pages = "490--497",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "3",

}

TY - JOUR

T1 - Modulation of macrophage-lymphocyte interactions by the antiarthritic gold compound, auranofin

AU - Griswold, D. E.

AU - Lee, J. C.

AU - Poste, George

AU - Hanna, N.

PY - 1985

Y1 - 1985

N2 - Auranofin (AF), a new oral gold agent effective for treating rheumatoid arthritis (RA), was evaluated for its ability to alter macrophage and lymphocyte functions of immune mediated chronic inflammation. AF (2 μM) inhibited antigen presentation by splenic macrophages to sensitized (DNFB) lymph node cells in vitro and also inhibited production of IL-2 and IL-1 by lymphocytes and macrophages, respectively. When AF suppressed Con-A induced mitogenesis in vitro, there were no inhibitory effects on Con-A induced suppressor T cell functions. AF administered orally to normal mice did not affect antigen presentation, DNFB contact sensitivity or Con-A induced mitogenesis. High concentrations of topical AF inhibited local immune responses to contact sensitizing agents and enhanced the induction of antigen specific suppressor T cells. Optimally, in vitro or in vivo AF inhibited macrophage and helper T cell functions with impairing the induction of suppressor T cells. After chronic treatment, similar effects could contribute to the efficacy of AF in humans with RA.

AB - Auranofin (AF), a new oral gold agent effective for treating rheumatoid arthritis (RA), was evaluated for its ability to alter macrophage and lymphocyte functions of immune mediated chronic inflammation. AF (2 μM) inhibited antigen presentation by splenic macrophages to sensitized (DNFB) lymph node cells in vitro and also inhibited production of IL-2 and IL-1 by lymphocytes and macrophages, respectively. When AF suppressed Con-A induced mitogenesis in vitro, there were no inhibitory effects on Con-A induced suppressor T cell functions. AF administered orally to normal mice did not affect antigen presentation, DNFB contact sensitivity or Con-A induced mitogenesis. High concentrations of topical AF inhibited local immune responses to contact sensitizing agents and enhanced the induction of antigen specific suppressor T cells. Optimally, in vitro or in vivo AF inhibited macrophage and helper T cell functions with impairing the induction of suppressor T cells. After chronic treatment, similar effects could contribute to the efficacy of AF in humans with RA.

UR - http://www.scopus.com/inward/record.url?scp=0021823601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021823601&partnerID=8YFLogxK

M3 - Article

C2 - 2931519

AN - SCOPUS:0021823601

VL - 12

SP - 490

EP - 497

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 3

ER -